Sangrix Restates December 2025 Interim Financials, Citing Material Errors
SGRX sits 27% above its 52-week low of $1.4 on light trading volume (0.3× avg).
Summary
Sangrix restated its December 2025 interim financials to correct material errors in equity classification, interest presentation, and warrant-related deemed dividends, with no change to total assets, liabilities, or consolidated net loss.
Key Events · Corporate Governance and Compliance · SGRX
-
Material Restatement of Interim Financials
Sangrix restated its unaudited condensed consolidated balance sheet as of December 31, 2025 and statement of operations for the six months then ended, concluding the errors were material under SAB No. 99.
-
Equity Reclassification
66,668 Class A Ordinary Shares with redemption rights were reclassified from permanent equity to mezzanine equity, a $4,201,307 adjustment that did not affect total assets, liabilities, or net loss.
-
Warrant Deemed Dividend Correction
The deemed dividend attributable to the down-round feature of outstanding warrants was reduced by $1,981,633, lowering net loss attributable to Sangrix from $18.4M to $16.4M.
-
Convertible Debenture Interest Presentation
Interest expense on convertible debentures measured under the fair value option was reclassified into the change in fair value line, with no effect on consolidated net loss.
Analysis · SGRX · Crypto Assets
Sangrix has restated its unaudited interim financial statements for the six months ended December 31, 2025, after concluding that errors in classifying redeemable shares, presenting convertible debenture interest, and measuring warrant-related deemed dividends were material. The restatement reclassifies $4.2 million of Class A shares to mezzanine equity and reduces the deemed dividend by roughly $2.0 million, but does not change total assets, total liabilities, or consolidated net loss. The filing also retroactively adjusts share and per-share amounts for two reverse splits completed in 2026. A restatement of this nature raises governance and financial-reporting concerns, even though the underlying economics are unchanged.
How filings like this one have moved
In the 30 days to Oct 1, 2026, 35.9% of the 1030 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.57%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, SGRX was trading at $1.78 on NASDAQ in the Crypto Assets sector, with a market capitalization of approximately $1.4M. The 52-week trading range was $1.40 to $166.71. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.